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Early Experience with Inhaled Nitric
Oxide for the Treatment of Infants and
Children with Pulmonary Hypertension
David Easa MD, Daniel I. Murai MD, Brian Oka ART, Marshall Dressel MD,
Paula Vanderford MD, Susan Pelke AN, and Venkataraman Balaraman MBBS
When nitric oxide (NO), an endogenous regulatorof smooth muscle
tone, is administered by inhalation, it acts as a selective pulmonary
vasodilator, This report details the treatment with inhaled NO of the
first 11 patients in Hawaii.
Introduction
This report describes the development of the inhaled nitric oxide
(NO) program and our initial experience with NO for pulmonary
hypertension at Kapiolani Medical Center for Women and Children
(KIVICWC). NO, a clear, colorless gas,’ is a component of the air we
breathe as measured in parts per billion (ppb).23 It also is found in
higher concentrations of parts per thousand (ppt) in cigarette
smoke.4 In higher concentrations, NO is toxic and capable of
causing acute pulmonary injury and death.5 Furthermore, in the
presence of oxygen, NO combines to form nitrogen dioxide (NO9),
another toxic gas.6 The Environmental Protection Agency set the
upper limit of exposure to NO and NO., at 25 ppm and 5 ppm,
respectively.7
Over the last few years, NO has been identified as the endothe
hum-derived relaxing factor (EDRF).8This factor facilitates smooth
muscle relaxation9 and is an endogenous regulator of smooth
muscle tone.’°’1 In the vascular endothelium, NO is synthesized
from the amino acid L—arginine,’° and readily diffuses into adjacent
smooth muscle cells where it activates guanylate cyclase to form
cyclic guanosine monophosphate (cGMP).’° cGMP mediates smooth
muscle relaxation by complex intracellular mechanisms.
This understanding of the role of NO in smooth muscle relaxation
led to its clinical use as a therapy for patients with pulmonary
hypertension. ‘i” It was determined that inhaled NO could reduce
pulmonary vasoconstriction and shunt fraction, thereby improving
oxygenation in these patients.’ ‘It also was found that inhaled NO is
a selective pulmonary vasodilator. As NO diffuses through the
smooth muscle cell into the blood vessel, it rapidly combines with
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hemoglobin to form methemoglobin;’°’5free NO does not circulate
in, and therefore does not affect, the systemic circulation.’2
As of 1994, it has been estimated that more than 1,000 patients
have been treated with inhaled NO worldwide. Subsequently, the
use of inhaled NO in infants and children with pulmonary hyperten
sion has
Methods
After review of the literature, consultation with national experts
and personal experience at Massachusetts General Hospital by one
of the authors (B 0), the Department of Neonatology at KMCWC
began the process of developing an NO therapy program for infants
and children. The Food and Drug Administration approved our
Investigational New Drug application for the rescue use of NO in
infants and children with documented pulmonary hypertension and
systemic hypoxemia. The protocol then was approved by our
medical center’s Institutional Review Board. In addition, separate
animal studies were carried out to gain experience with NO admin
istration before subjecting human infants to this new form of
therapy. The following equipment and supplies were necessary
(Fig 1).
Nitric oxide.—Nitric oxide is mixed with nitrogen (N2)as an inert
diluent at a concentration of 800 ppm.
Blender and connections—Levels of NO concentration were
adjusted using a blender connected with oxygen. The concentration
of NO was measured by electrochemical analysis in parts per
million.
Fig 1.—Basic nitric oxide (NO) delivery system using a double blendertechnique
and NO analyzer, modified for a time-cycled, pressure-limited infant ventilator.
Reprinted with permission.2’
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Pulmonox electrochemical analyzer.—Electrochemical analy
sis was used for all NO and nitrogen dioxide measurements
(Pulmonox II, Pulmonox Research and Development Corp, Alberta,
Canada).
Exhalation scavenging device.—The exhalation block of the
ventilator was enclosed by a custom-made plastic bottle connected
to the wall vacuum set at -100 cmH2O.NO, analysis verification was
performed around this scavenging system with a Drager NO,
chemical analyzer.
Ventilators.—NO was utilized only with conventional ventila
tors (Sechrist Infant Ventilator, Sechrist Industries, Anaheim, Cali
fornia; Servo 900C Ventilator, Siemens-Elema, Sweden).
Methemoglobin analyzer.—Methemoglobin levels were ana
lyzed utilizing a co-oximeter (2500 Series, Ciba Corning, Medfield,
Massachusetts) at 1, 2 and 4 hours after initiation of NO, then every
6 to 8 hours until stable while on 40 ppm. When NO was weaned
to <40 ppm, methemoglobin levels were followed every 12 hours.
Eligibility criteria.—To receive NO, patients were required to
meet the following criteria: 1) 34 weeks of gestation for infants;
2) evidence of pulmonary hypertension by systemic hypoxemia
(AaDO2 600 torr or PaO, 70 ton in FiO, 1.0 on two arterial blood
gases 30 minutes apart) with echocardiographic confirmation of
pulmonary hypertension; 3) poor response to conventional or high
frequency ventilation with mean airway pressure >12 cmHO; 4)
increasing inotropic drug support; and 5) informed parental con
sent. We excluded infants with inoperable life-threatening anoma
lies. Common diagnostic categories included meconium aspiration
syndrome, pneumonia and sepsis, diaphragmatic hernia, acute
respiratory distress syndrome (ARDS), and postoperative patients
with congenital heart disease.
Procedures.—Infants were placed on the conventional ventilator
with the NO blender attached. We frequently attempted to use
respiratory alkalosis therapy (pH 7.6 and PaCO, 20 ton) to
ensure adequate lung expansion and improve the chances for
response to NO therapy during NO insufflation.
We used an initial dose of 40 ppm to 80 ppm. This dose allowed
the clinician to immediately differentiate between responders and
non-responders. Response was defined in an infant as a twofold
increase in PaO2.Failure to respond to NO therapy is an important
determination and could be criteria to transfer the infant for extra-
corporeal membrane oxygenation (ECMO) therapy.
Determination of response to NO was usually made in the first 30
minutes after initiation. If the patient was a responder, small
decreases iii NO concentrations were made in proportion to the
extent of the increase in PaO, >150 ton. The reductions were as
small as 5 ppm to as great as 20 ppm at any one time. The goal was
to lower the NO concentrations as quickly as possible to 5 to 6 ppm
to reduce the risk of methemoglobin or NO, toxicity.6’°’ Accord
ingly, NO was preferentially weaned before attempting any reduc
tion in oxygen or ventilator settings.
Non-ventilator conventional management continued during NO
therapy and included minimal stimulation, medications such as
fentanyl, Versed and pancuronium, pulmonary physiotherapy and
suctioning. We maintained mean arterial pressures between 60
mmHg to 75 mmHg with varying combinations of dopamine,
dobutamine, and amrinone and with fluid boluses.
Results
Of the 11 patients treated with NO to date, one was admitted to the
pediatric intensive care unit; the others were neonates admitted to
the neonatal intensive care unit. Two of these infants were trans
ferred from other hospitals (Kaiser Medical Center, Tripler Army
Medical Center) for NO therapy; two were transferred from other
islands for treatment of congenital heart disease and diaphragmatic
hernia; the remaining patients were born at KMCWC.
Seven of the II patients responded to NO therapy, with a mean
increase in PaO, of 166 ton within 12 hours after NO was started.
One infant, whose PaO, did not respond dramatically or consistently
to NO, was considered a responder because his condition stabilized
and he became easier to manage once NO was begun. NO was
administered for an average of 105 hours (range 1 to 469 hours). The
baseline methemoglobin level was <2% in all but one infant, whose
initial level after beginning NO at 60 ppm was 4.3. However, this
level rapidly decreased to 1.1 within one hour after reducing the NO
to 40 ppm. Otherwise, the maximum methemoglobin level recorded
during therapy was 2.6. Platelet counts were normal or near normal.
Four patients did not respond to NO therapy. The first
nonresponding infant had meconium aspiration syndrome and poor
cardiac contractility, both factors known to decrease the success of
NO therapy. This infant survived after transport to the Mainland for
ECMO. Another nonresponding infant in retrospect was thought to
have more pulmonary than pulmonary-vascular disease. The last
nonresponding infant had congenital diaphragmatic hernia and died
of that primary diagnosis. The only older child treated with NO was
a three-year old who was critically ill with ARDS and pre-existing
central nervous system disease. He was treated with NO for only one
hour after not responding to conventional therapy. He did not
respond to NO and died of his other diagnoses.
A summary of treatment and outcome information is shown in
Table 1; the average oxygenation index (0!) is plotted before and
after NO therapy in the responding and nonresponding infants in
Figure 2.
Table 1.—Nitric Oxide Treatment and Outcome Data
Pt Birth Diagnoses Treatment Maximum Pa02 Outcome
No Weight Duration Dose Pre/Post
NO
1 2840 MAS 2 hr 80 54/34 ECMO
survived
2 2650 MAS/pneumothorax 122 hr 40 73/297 survived
anatomic
brain
anomaly
3 3020 coarctation 469 hr 20 65/365 survived-
seizure
disorder
4 4600 pneumonia/DIC 76 hr 60 38/216 survived
5 3 yo ARDS 1 hr 80 46/45 died
6 2790 MAS/pneumonia 112 hr 40 53/120 survived
7 3731 MAS/blood 170 hr 52 90/270 survived
aspiration/
pneumonia
8 3365 MAS/pneumothora 72 hr 40 43/1 72 survived
pneumonia
9 3722 MAS/pneumonia 4 hr 60 82/84 survived
10 3099 CDH l4hr 80 48/42 died
11 3610 MAS/pneumonia 114 hr 40 67/150 survived
NO, nitric oxide; MAS, meconium aspiration syndrome: ECMO, extracorporeal membrane
oxygenation; DIC, disseminated intravascular coagulopathy; ARDS, acute respiratory
distress syndrome; CDH, congenital diaphragmatic hernia.
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Discussion
Although anecdotal, we are encouraged that NO contributed
significantly to the survival and recovery of these critically ill
infants who were not responding to conventional therapies. Ran
domized, controlled trials comparing NO to conventional therapy
will be needed to definitively prove the value of NO therapy; such
trials are currently being conducted in other centers. However, it is
clear from anecdotal experience from other tertiary centers around
the country that there is significant variability in response to NO
therapy from center to center.
At this point in our experience, several observations suggest there
are important factors enhancing the success ofNO therapy. The four
most important factors associated with a good response include:
high systemic arterial pressures (means of> 60 mmHg); adequate
lung volume as evaluated by frequent chest x-rays; normal cardiac
contractility; and maintenance of respiratory alkalosis with pH 7.6
and PaCO, 20 torr.
When the above factors were controlled, the lability in oxygen
ation was dramatically reduced, especially during attempts to wean
the infant from ventilator support. Lability in oxygenation is of
concern since it indicates the presence of pulmonary vasospasm
which could lead to severe hypoxemia, acidosis, and death. Previ
ously, systemic vasodilators such as tolazoline were used in an
attempt to reduce this lability.’8However, these drugs frequently
dilated both pulmonary and systemic vascular beds resulting in
systemic hypotension and further instability.’9Because inhaled NO
is inactivated by immediately combining with hemoglobin after
diffusing into the systemic circulation,’°”5 it acts as a selective
pulmonary vasodilator. Neither systemic hypotension nor lability
of oxygenation was observed in infants responding to NO treatment.
Thus, any deterioration during weaning attempts was easily re
versed by returning to baseline conditions. Finally, this stability in
oxygenation should promote future confidence in the treatment of
these infants, knowing that the use of NO allows for more forgiving
clinical management.
Until the benefits of this therapy are proved in randomized trials
and adequate followup studies, we believe the most important
consideration in the use of NO is safety.’°”2° should be used in
the lowest concentration possible in order to avoid any potential
toxic effects.2°
In summary, we have presented the background knowledge and
process that led to our use of this experimental therapeutic gas. Our
initial experience with NO therapy has been encouraging, and we
anticipate greater success with more experience. Furthermore, we
speculate that future uses for inhaled NO therapy will be found other
than those characterized strictly by pulmonary hypertension. These
may include such conditions as bronchopulmonary dysplasia, chronic
lung disease, viral and bacterial pneumonia, respiratory distress
syndrome, and ARDS. Oxygenation in these disorders may im
prove from the reduction in shunt fraction seen with the use of this
selective pulmonary vasodilator.2°
Acknowledgments
We thank Kapiolani Medical Center for Women and Children for
support with equipment purchases and the Respiratory Care and
Neonatal Intensive Care Unit nursing staff for their expertise in
implementing this program.
Addendum
Since submission of this paper, we have treated an additional 19
infants with NO. Thirteen of the last 15 treated infants responded to
NO; the only infant who died had pulmonary hypertension compli
cated by diaphragmatic hernia. We believe that the improved
response and survival were due to the beneficial effects of a learning
curve. Furthermore, we credit the improvement in results to the
liberal use of fluids to expand blood volume, pressors to maintain
blood pressure, exogenous surfactant to reverse surfactant dysfunc
tion, and diuretics after the initial period of stabilization to reduce
pulmonary congestion. Finally, our current approach is to begin NO
at 20 ppm and increase to 40 ppm only when necessary.
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Fig 2.—Oxygenation Index (01) values in 7 responding and 4 nonresponding
patients to inhaled nitric oxide. Values represent mean ± standard deviation. 01
= (Mean airway pressure x FlO, x 100)/Pa02.
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